These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14981585)

  • 1. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.
    Glover KY; Perez-Soler R; Papadimitradopoulou VA
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):83-92. PubMed ID: 14981585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
    Sridhar SS; Seymour L; Shepherd FA
    Lancet Oncol; 2003 Jul; 4(7):397-406. PubMed ID: 12850190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of EGFR inhibitors in nonsmall cell lung cancer.
    Ciardiello F; De Vita F; Orditura M; Tortora G
    Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
    Bonomi P
    Lung Cancer; 2003 Aug; 41 Suppl 1():S43-8. PubMed ID: 12867061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
    Bonomi PD
    Am J Health Syst Pharm; 2003 Dec; 60(24 Suppl 9):S16-21. PubMed ID: 14717024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
    Kelly K; Averbuch S
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD1839 (Iressa): what's in it for the patient?
    Natale RB; Zaretsky SL
    Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma.
    Jänne PA
    Ann Med; 2003; 35(7):450-7. PubMed ID: 14649327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N; Belani C
    Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib (Iressa) trials in non-small cell lung cancer.
    Johnson DH
    Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.